These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. Edris F; Vilos GA; Al-Mubarak A; Ettler HC; Hollett-Caines J; Abu-Rafea B J Minim Invasive Gynecol; 2007; 14(1):68-73. PubMed ID: 17218233 [TBL] [Abstract][Full Text] [Related]
43. Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis. Magini A; Pellegrini S; Tavella K; Forti G; Massi GB; Serio M J Endocrinol Invest; 1993 Nov; 16(10):775-80. PubMed ID: 8144850 [TBL] [Abstract][Full Text] [Related]
44. Fertility-Sparing Treatment of Early Endometrial Cancer and Complex Atypical Hyperplasia in Young Women of Childbearing Potential. Pronin SM; Novikova OV; Andreeva JY; Novikova EG Int J Gynecol Cancer; 2015 Jul; 25(6):1010-4. PubMed ID: 25950126 [TBL] [Abstract][Full Text] [Related]
45. The degree of fluid absorption during hysteroscopic surgery in patients pretreated with goserelin. Taskin O; Yalcinoglu A; Kucuk S; Burak F; Ozekici U; Wheeler JM J Am Assoc Gynecol Laparosc; 1996 Aug; 3(4):555-9. PubMed ID: 9050688 [TBL] [Abstract][Full Text] [Related]
46. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. Sarosdy MF; Schellhammer PF; Soloway MS; Vogelzang NJ; Crawford ED; Presti J; Chodak GW; Mitchell P; Porter L BJU Int; 1999 May; 83(7):801-6. PubMed ID: 10368200 [TBL] [Abstract][Full Text] [Related]
47. [New possibilities for differentiated therapy of leiomyoma of the uterus using the GnRH agonist zoladex]. Gesenhues T; Hackenberg R; Diechert U; Duda V; Sturm G; Schulz KD Geburtshilfe Frauenheilkd; 1989 Feb; 49 Suppl 1():96-8. PubMed ID: 2522904 [TBL] [Abstract][Full Text] [Related]
48. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma. Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417 [TBL] [Abstract][Full Text] [Related]
49. Zoladex (goserelin acetate) and the anemic patient: results of a multicenter fibroid study. Benagiano G; Kivinen ST; Fadini R; Cronjé H; Klintorp S; van der Spuy ZM Fertil Steril; 1996 Aug; 66(2):223-9. PubMed ID: 8690106 [TBL] [Abstract][Full Text] [Related]
50. [The relationship between simple and atypical endometrial hyperplasia and endometrial carcinoma]. Borisov I; Maĭnkhard K; Tsankova M Akush Ginekol (Sofiia); 1996; 35(4):18-20. PubMed ID: 9254559 [TBL] [Abstract][Full Text] [Related]
51. Role of goserelin-depot in the clinical management of uterine fibroids. Cagnacci A; Paoletti AM; Soldani R; Angiolucci M; Arangino S; Falqui A; Melis GB Clin Exp Obstet Gynecol; 1994; 21(4):263-5. PubMed ID: 7994879 [TBL] [Abstract][Full Text] [Related]
52. [Treatment of benign uterine hemorrhage and simple endometrial hyperplasia by endometrial ablation]. Grio R; Geranio R; Curti A; Piacentino R; Ferraris GP Minerva Ginecol; 1999; 51(1-2):49-51. PubMed ID: 10230246 [TBL] [Abstract][Full Text] [Related]
53. Hysteroscopy in Abnormal Uterine Bleeding vs Ultrasonography and Histopathology Report in Perimenopausal and Postmenopausal Women. Sharma J; Tiwari S JNMA J Nepal Med Assoc; 2016; 55(203):26-28. PubMed ID: 27935919 [TBL] [Abstract][Full Text] [Related]
54. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer. Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636 [TBL] [Abstract][Full Text] [Related]
55. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024 [TBL] [Abstract][Full Text] [Related]
57. Hysteroscopic evaluation of intrauterine progesterone contraceptive system as a treatment for abnormal uterine bleeding. Scarselli G; Mencaglia L; Tantini C; Colafranceschi M; Taddei G Acta Eur Fertil; 1984; 15(4):279-82. PubMed ID: 6240880 [TBL] [Abstract][Full Text] [Related]
58. Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas. Bianchi S; Fedele L; Vignali M; Galbiati E; Cherubini R; Ortolani S Calcif Tissue Int; 1995 Jul; 57(1):78-80. PubMed ID: 7671171 [TBL] [Abstract][Full Text] [Related]